Stephan Von Schilcher, global strategic account manager at Systech, discusses the repercussions of counterfeit drug epidemic on patients and what pharma companies must to combat the problem.
Key Highlights:
Mapping the counterfeit and diversion epidemic in the pharma industry
Stephan Von Schilcher, global strategic account manager at Systech, discusses the repercussions of counterfeit drug epidemic on patients and what pharma companies must to combat the problem.
Published:
|
4 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.